Stay updated with breaking news from Hemodynamic Instability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- VitalConnect®, Inc., an award-winning leader in remote and in-hospital wearable biosensor technology, today announced a relationship with Fifth...
/PRNewswire/ -- Fifth Eye brings AHI System – the most advanced predictive patient monitoring technology available today – to HLTH 2023 in Las Vegas, October...
/PRNewswire/ -- Fifth Eye™, a leading provider of real-time AI-based clinical analytics today announced that its Board of Directors has appointed Andrew...
Press release content from PR Newswire. The AP news staff was not involved in its creation. FDA Grants De Novo to ML-based, Real-time Indicator of Patient Deterioration March 2, 2021 GMT ANN ARBOR, Mich., March 2, 2021 /PRNewswire/ -- Fifth Eye TM, a provider of intuitive real-time clinical analytics, today announced the U.S. Food and Drug Administration (FDA) has granted De Novo classification for its Analytic for Hemodynamic Instability (AHI). AHI can continuously monitor any patient with an electrocardiogram (ECG) for hemodynamic instability — a leading cause of death for critically ill ...
Share Fifth Eye, a Michigan-based real-time clinical analytics company, announced today that the Food and Drug Administration has granted De Novo classification for its Analytic for Hemodynamic Instability (AHI) tool. The technology links with hospitals' existing electrocardiograms to create a reading of patients' hemodynamic status every two minutes. Once AHI completes a reading, it uses machine learning to generate patient updates without vital sign assessment, manual data input in electronic health records or score calculation. "The reason we tackled this problem is to provide the ad...